DETROIT, MI — A new study from the Henry Ford Health System may provide more legitimacy on the use of hydroxychloroquine to treat COVID-19.
Henry Ford published the peer-reviewed study on July 1, using a large-scale retrospective analysis of patients from March 10 to May 2. The study looked over 2,500 hospitalized patients from the Henry Ford’s six hospitals, said Dr. Marcus Zervos, division head of infectious disease for Henry Ford Health System....
The study concluded that treatment with hydroxychloroquine significantly reduces the death rate of COVID-19 patients, Zervos said. Of those treated with hydroxychloroquine alone, 13% of them died, compared to the 26.4% who died and were were not treated with the drug. There was an overall 18.1% in-hospital mortality rate and patients were over the age of 18, with a median age of 64.
Conservative. Idaho. Software engineer. Historian. Trying to prevent Idiocracy from becoming a documentary.
Email complaints/requests about copyright infringement to clayton @ claytoncramer.com. Reminder: the last copyright troll that bothered me went bankrupt.
Pages
▼
Saturday, July 4, 2020
Hydroxychloroquine
Remember the leftist media denigrating hydroxychloroquine because Trump thought it had great promise? That is because they assume everything he says is either a lie or incorrect. Fake news describes the national news media.
Agree that the media was outrageous about this. And, it looks like the fact that Trump hyped HCQ may have led a lot of doctors to not want to use it - because, hey, Orange Man Bad.
ReplyDeleteI think the verdict is still out. My guess would be that HCQ is best used early in the course of illness, when defeating the virus is the key. Once the immune system over-reaction gets going, it may be too late. And, most trials were of people already hospitalized, many of whom were thus probably poor candidates.
But, we just don't know. Lots of such drugs - with theoretical and in-vitro (test tube, etc) promise - don't work out well in humans (in-vivo).